InvestorsHub Logo
Followers 797
Posts 50895
Boards Moderated 1
Alias Born 12/12/2004

Re: None

Wednesday, 08/31/2022 8:40:58 AM

Wednesday, August 31, 2022 8:40:58 AM

Post# of 1456
SEC filing 8-k > On August 30, 2022, Oncternal Therapeutics, Inc. submitted an Investigational New Drug Application (“IND”) for ONCT-808, its autologous chimeric antigen receptor T cell (CAR-T) targeting Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). The IND must be accepted by the U.S. Food and Drug Administration prior to commencing a clinical study of ONCT-808.

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News